BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Market News

McDonald’s earnings growth slows to 5% as currency masks flat constant-currency momentum

Moe Alsumidaie by Moe Alsumidaie
August 18, 2026
in Market News
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

McDonald’s reported second-quarter net income of $2,362 million, up 5 percent from $2,253 million a year earlier, with diluted earnings per share rising 6 percent to $3.32. But the headline gain masks a weaker underlying picture: in constant currencies, stripping out the $0.03 per share benefit from foreign exchange translation, earnings per share grew only 5 percent. For the six-month period, the company posted net income of $4,345 million, up 5 percent, and earnings per share of $6.10, up 6 percent, though constant-currency earnings per share growth slowed to 3 percent. The company provided no forward guidance in this filing.

Quarterly revenues reached $7,099 million, up from $6,843 million in the prior year quarter, a 4 percent increase that becomes 3 percent when currency translation is removed. Franchised revenues, which represent the bulk of the business model, grew 4 percent to $4,393 million, or 3 percent in constant currencies. Company-owned and operated sales grew 3 percent to $2,525 million, or flat in constant currencies. For the six-month period, revenues of $13,616 million compared to $12,799 million a year prior, a 6 percent reported gain that narrows to 6 percent in constant currencies. The company incurred restructuring charges of $52 million, or $0.06 per share, in the quarter as part of its “Accelerating the Organization” modernization effort.

What it means

McDonald’s growth is running substantially below its full-year 2025 revenue growth rate of 3.7 percent when currency effects are stripped away. The six-month constant-currency revenue growth of 6 percent appears stronger, but that figure includes an easier comparison to the first half of 2025 and masks a deceleration visible in the quarterly print. Franchised revenues, the company’s primary earnings driver, grew only 3 percent in constant currencies during the quarter, suggesting that underlying franchisee sales momentum is modest. Company-owned restaurant sales were flat in constant currencies, indicating no organic lift from the company’s own operations.

The currency tailwind is material and temporary. Foreign exchange translation added $0.03 per share in the quarter and $0.17 per share for the six months, accounting for roughly half of the reported earnings per share growth in the period. The company notes that most major currencies strengthened against the dollar, primarily the Euro and Australian Dollar. This benefit will reverse if those currencies weaken, and it masks the fact that underlying operational earnings growth is running at or below low single digits in constant currency terms.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: MCDONALDS CORP and 500+ other names, on the same official data.See the evidence engine →

The open question is whether the modest constant-currency growth reflects a temporary softness in franchisee sales or a structural slowdown in the business. The document does not disclose comparable sales growth, which would indicate whether the growth in franchised revenues stems from new unit development or from same-store sales increases at existing locations. Without that metric, it is impossible to determine whether the company is growing through expansion or facing headwinds in like-for-like sales.

Source: the company’s 8-K filed 2026-08-04 with the SEC.

BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read MCDONALDS CORP’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Procter & Gamble accelerates organic sales growth to 4% as pricing and volume both contribute

by Moe Alsumidaie
October 23, 2026
0

Procter & Gamble's first quarter of fiscal 2027 delivered organic sales growth of 4 percent, up from the prior year's 3.3 percent, driven b

Read moreDetails

Abbott to split Nutrition into independent company with $8.5 billion in sales by end of 2027

by Moe Alsumidaie
October 22, 2026
0

Abbott announced plans to separate its Nutrition business into a standalone publicly traded company by the end of 2027, creating a $8.5 bil

Read moreDetails

GE Aerospace raises 2026 guidance as commercial services orders surge 58 percent

by Moe Alsumidaie
October 21, 2026
0

GE Aerospace lifted full-year profit and cash flow targets after third-quarter orders jumped 58 percent, driven by a backlog of over $170 b

Read moreDetails

Biohaven licenses Japan and Asia rights to Graves’ disease candidate for $80 million upfront and 20% royalties

by Moe Alsumidaie
October 19, 2026
0

Biohaven has licensed its lead extracellular IgG degrader, BHV-1300, to Ono Pharmaceutical for exclusive development and commercialization

Read moreDetails

UnitedHealth’s operating margin surges as medical cost discipline offsets revenue decline

by Moe Alsumidaie
October 15, 2026
0

UnitedHealth Group raised full-year earnings guidance to at least $20.50 per share after third-quarter operating earnings jumped 53 percent

Read moreDetails
Next Post

McDonald's names Skye Anderson as USA president, replacing Joe Erlinger after seven-year tenure

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Biohaven licenses Japan and Asia rights to Graves’ disease candidate for $80 million upfront and 20% royalties

October 19, 2026

Evidence Sheet: American Airlines Group (AAL)

August 10, 2026

JPMorgan: Record Earnings, a 99th-Percentile Price Tag, and One Open Question

August 25, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.